Biotech Growth Rate outperforming classical pharmaceuticals

Description:

Over the last years, the growth rate of biotech industry has by far outperformed the one of the classical pharma industry. This has not had a positive impact on the profitability of biotech as such – profitability of most classical pharma majors is still higher than the one of most biotech companies – but it has shown in the development of stock prices. Biotechnology stocks have outperformed the ones of classical pharma majors thanks to the hope for future profits.

Enablers:

• Hope for good profit margins
• Hope for huge ROE
• Potential for spectacular breakthroughs in Research.

Inhibitors:

• Increase (instead of decrease) of R&D cost in biotechnology

• Decrease in R&D costs for classical drugs

• Entry barriers getting lower because of increased availability of fundamental research

• Drug Approval regulations getting stricter

• Insecurity regarding the development of legal frameworks

• Price Pressure due to exploding healthcare cost

Paradigms:

• Investors look elsewhere

Experts:

See our Research regarding Growth and Development issues

Web Resources:

See our Research regarding Growth and Development issues